Importance of early absolute lymphocyte count after allogeneic stem cell transplantation: a retrospective study

Transplantation Proceedings
Lisandra RigoniLiane Daudt

Abstract

Early lymphocyte recovery after allogeneic hematopoietic stem cell transplantation (HSCT) is related to the prevention of serious infections and the clearing of residual tumor cells. We analyzed the absolute lymphocyte count at 20 (D+20) and 30 (D+30) days after HSCT in 100 patients with malignant hematologic diseases and correlated with the risk of transplant-related mortality, overall survival (OS), disease-free survival (DFS), nonrelapsed mortality (NRM), and risk of infection. Patients presenting with lymphocyte counts of <300 × 103/μL on D+30 have a 3.76 times greater risk of death in <100 days. Over a medium follow-up of 20 months OS, DFS, and NRM were similar between the groups. In our group of patients delayed lymphocyte recovery after HSCT was a predictor of early death post-HSCT.

References

Apr 3, 2004·British Journal of Haematology·Dong Hwan KimKyu Bo Lee
Dec 1, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcel P Devetten, Julie M Vose
Mar 22, 2005·Bone Marrow Transplantation·J J Auletta, H M Lazarus
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Fermin M Sanchez-GuijoJesus F San Miguel
Oct 7, 2005·Critical Reviews in Oncology/hematology·Daniel H Fowler
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
Nov 30, 2006·Annual Review of Immunology·Lisbeth A WelniakWilliam J Murphy
Sep 16, 2008·Best Practice & Research. Clinical Haematology·Kirsten M Williams, Ronald E Gress
Aug 29, 2009·Blood·Gerard Socié, Bruce R Blazar
Sep 9, 2009·British Journal of Haematology·Olle RingdénMichael Uhlin
Nov 30, 2010·Bone Marrow Transplantation·L BühlmannM Stern
Dec 4, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O CiureaRichard E Champlin

❮ Previous
Next ❯

Citations

Nov 3, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ulas D BayraktarStefan O Ciurea
Nov 22, 2016·Bone Marrow Transplantation·A M AliM A Schroeder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.